Ascletis Pharma announced two poster presentations on its obesity assets at ObesityWeek 2026, which runs November 14 to 17 in Washington, DC. The two candidates are ASC48, an oral small molecule GIPR agonist, and ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist.

The company describes the material as preclinical. In the release, founder and CEO Jinzi Jason Wu said Ascletis was excited to present "the latest preclinical progress" of its obesity portfolio, which means no human results are attached to either poster.

What the two candidates are

GIPR, GLP-1R and GCGR are receptors that incretin and metabolic drugs act on, and the current generation of obesity drugs works by hitting one or two of them. ASC37 targets three at once and is designed, per the company, for once-monthly to once-quarterly subcutaneous dosing.

ASC48 is the other half of the pitch: a small molecule rather than a peptide, taken orally. Ascletis also lists it as the GIPR component of ASC30_48FDC, a once-daily oral fixed-dose combination with its lead program ASC30, a GLP-1R agonist.

A very long pipeline

The release names more than a dozen candidates and combinations, from oral triple agonists to a quadruple peptide fixed-dose combination. Ascletis attributes this to three in-house platforms, including one for extending duration of action and one it calls Peptide Oral Transport ENhancement Technology, aimed at making peptides work by mouth.

That breadth is the most interesting thing in the announcement and also the reason to read it carefully. A pipeline built largely on fixed-dose recombinations of four or five in-house molecules can look much larger than the amount of underlying clinical evidence behind it.

What is not in the release

No efficacy figure, no weight-loss number, no model species and no study design appear anywhere in the announcement. There is a presentation slot, a time and a pair of molecule names.

Ascletis is listed in Hong Kong, and press releases like this one are as much investor communication as scientific disclosure. The posters themselves, not the release, are where any data will actually be.

Bottom line

Two preclinical posters on an oral GIPR agonist and a triple peptide agonist go up on November 14, and until then the field has molecule names and a dosing ambition. Whether once-monthly or once-quarterly injectable triple agonism survives contact with human trials is the question this announcement does not answer.